77,403 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Transamerica Financial Advisors LLC

Transamerica Financial Advisors LLC purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 2nd quarter, HoldingsChannel reports. The firm purchased 77,403 shares of the biotechnology company’s stock, valued at approximately $6,309,000.

A number of other hedge funds have also modified their holdings of ARWR. Carolina Wealth Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. CWM LLC increased its stake in shares of Arrowhead Pharmaceuticals by 1.4% in the fourth quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock worth $820,000 after acquiring an additional 168 shares during the period. First Horizon Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 36.2% during the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 174 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Arrowhead Pharmaceuticals by 1.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after purchasing an additional 178 shares during the period. Finally, Optiver Holding B.V. lifted its position in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director directly owned 31,600 shares of the company’s stock, valued at $2,747,936. The trade was a 5.95% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $89.12 on Thursday. The stock has a market capitalization of $12.55 billion, a P/E ratio of -39.61 and a beta of 1.27. The company’s fifty day moving average price is $83.44 and its 200 day moving average price is $73.29. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $21.06 and a 1 year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. During the same period in the previous year, the business earned ($1.26) earnings per share. The business’s revenue for the quarter was up 171.0% on a year-over-year basis. As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Chardan Capital lifted their price objective on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price target for the company. JPMorgan Chase & Co. upped their price objective on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $97.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.